Yuri A. Zárate
Associate Professor, Geneticis
Also affiliated: Cincinnati Children's Hospital Medical Center (2007–2009); University of Kentucky HealthCare (2025); Arkansas Children's Hospital (2013–2024); University of Kentucky (2023–2026); University of Arkansas Medical Center (2015–2020); Centre for Life (2016); Muscular Dystrophy UK (2016); Mayo Clinic in Florida (2018); Pediatrics and Genetics (2010–2025); Greenwood Genetic Center (2010–2012); University of Cincinnati (2007–2009)
Faculty Researcher
Peds Pediatrics, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Yuri A. Zárate's research focuses on the genetic underpinnings of neurodevelopmental and congenital disorders. His work investigates the relationship between genetic variants and observable phenotypes, particularly in children. Zárate has published on topics including intellectual disability, mesomelic dysplasia, horseshoe kidney, and epileptic encephalopathy associated with variants in genes such as AFF3 and MYCBP2. His research also explores the genetic basis of corpus callosum defects and complex neurological disorders linked to genes like INTS11.
Further investigations by Zárate include the role of de novo coding variants in genes like AGO1 in causing neurodevelopmental disorders and intellectual disability. He has also examined the impact of both loss-of-function and gain-of-function variants in CDK19 on related disorders. Additionally, his work has contributed to understanding the genetic landscape of conditions like blue cone monochromacy, specifically focusing on structural variants at the OPN1LW/OPN1MW gene cluster.
Zárate leads a research group and has a significant publication record, with 147 publications and over 3,100 citations, reflected in his h-index of 28. He is recognized as a highly cited researcher. His collaborations include 11 shared publications with Katherine B. Bosanko at the University of Arkansas for Medical Sciences, as well as collaborations with Anna Blackshare, Larry D. Hartzell, and Aaron Hiegert.
Metrics
- h-index: 28
- Publications: 147
- Citations: 3,164
Selected Publications
-
Cognitive function depends upon <i>Satb2</i> gene dosage in cortical projection neurons (2026)
-
Evidence-based classification of genes implicated in craniosynostosis disorders using the ClinGen curation framework (2026)
-
Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification (2026)
-
Prioritizing topics for a clinical practice guideline on SATB2-associated syndrome: methodological rigor vs clinical usability (2026)
-
Functional characterization of pathogenic SATB2 missense variants identifies distinct effects on chromatin binding and transcriptional activity (2025)
-
‘Knowing and Treating Kosaki/Penttinen syndrome’ international collaborative consortium: recommendations for follow-up, natural history and a real-life observational study about safety and efficacy profile of tyrosine kinase inhibitors (2025)
-
Functional characterization of pathogenic SATB2 missense variants identifies distinct effects on chromatin binding and transcriptional activity (2025)
-
Artificial intelligence-driven genotype–epigenotype–phenotype approaches to resolve challenges in syndrome diagnostics (2025)
-
Individuals with SATB2-associated syndrome have impaired vitamin and energy metabolism pathways (2024)
-
Pathogenic <i>SATB2</i> missense variants affecting p.Gly392 have variable functional implications and result in diverse clinical phenotypes (2024)
-
Abnormalities in pharyngeal arch‐derived structures in SATB2‐associated syndrome (2024)
-
<i>NR3C2</i> microdeletions—an underrecognized cause of pseudohypoaldosteronism type 1A: a case report and literature review (2024)
-
Listening to patients with suspected genetic diagnoses: A narrative perspective (2023)
-
THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial (2023)
-
Bone health in <i>SATB2</i>‐associated syndrome: Results from a large prospective cohort and recommendations for surveillance (2023)
Grants & Funding
As listed on this researcher's institutional profile.
- Novel role of immunoproteaseome during renal cold storage and transplantation UAMS College of Medicine Principal Investigator
- Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS) Core? Arkansas Center and Stillbirth NIH Co-Investigator
- RII Track 2 FEC: Multi-scale Integrative Approach to Digital Health: Collaborative Research and Education in Smart Health in West Virginia and Arkansas" National Science Foundation via West Virginia University Principal Investigator
- Patient and Stakeholder Alliance for SATB2-Associated Syndrome UAMS ACHRI Flow Through Principal Investigator
- RFA-DD-18-001 Birth Defects Study To Evaluate Pregnancy exposures (BD-STEPS) II Core & Component B Steps -Stillbirth NIH Co-Investigator
- EPSCoR - CASE Summer National Science Foundation via Arkansas Economic Development Commission Principal Investigator
Collaboration Network
Top Collaborators
- <scp><i>SATB2</i>‐associated</scp> syndrome in adolescents and adults
- Growth in individuals with <i>SATB2</i>‐associated syndrome
- Individuals with SATB2-associated syndrome with and without autism have a recognizable metabolic profile and distinctive cellular energy metabolism alterations
- Abnormalities in pharyngeal arch‐derived structures in SATB2‐associated syndrome
- Quantitative Phenotype Morbidity Description of SATB2-Associated Syndrome
Showing 5 of 8 shared publications
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Design of the ACcomplisH Trial: A Phase 2, Multicenter, Placebo-Controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Weekly TransCon CNP in Children With Achondroplasia
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Design of the ACcomplisH Trial: A Phase 2, Multicenter, Placebo-Controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Weekly TransCon CNP in Children With Achondroplasia
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- A clinical scoring system for early onset (neonatal) Marfan syndrome
- Craniosynostosis is a feature of Costello syndrome
- Genetic and phenotypic heterogeneity in <scp>KIAA0753</scp>‐related ciliopathies
- OP023: A clinical scoring system for early onset (neonatal) Marfan syndrome
- A dyadic approach to the delineation of diagnostic entities in clinical genomics
- Response to Hamosh et al.
- Listening to patients with suspected genetic diagnoses: A narrative perspective
- A dyadic approach to the delineation of diagnostic entities in clinical genomics
- Craniosynostosis is a feature of Costello syndrome
- Response to Hamosh et al.
- <scp><i>SATB2</i>‐associated</scp> syndrome in adolescents and adults
- Growth in individuals with <i>SATB2</i>‐associated syndrome
- Quantitative Phenotype Morbidity Description of SATB2-Associated Syndrome
- A clinical scoring system for early onset (neonatal) Marfan syndrome
- Prevalence and Outcomes of Primary Left Ventricular Dysfunction in Marfan Syndrome
- OP023: A clinical scoring system for early onset (neonatal) Marfan syndrome
- A clinical scoring system for early onset (neonatal) Marfan syndrome
- Prevalence and Outcomes of Primary Left Ventricular Dysfunction in Marfan Syndrome
- OP023: A clinical scoring system for early onset (neonatal) Marfan syndrome
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
- Once-Weekly TransCon CNP in Children with Achondroplasia (ACcomplisH): A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
- THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
Similar Researchers
Based on overlapping research topics